

SUPPLEMENTARY MATERIAL

Utilization trends and impact of secukinumab treatment on clinical outcomes in biologic-naïve patients with psoriasis in a US real-world setting

Bruce Strober, MD, PhD,^{1,2} Dhaval Patil, MS, BPharm,³ Robert R. McLean, DSc, MPH,⁴ Melissa Moore-Clingenpeel, MA, MAS,⁴ Ning Guo, MSc,⁴ Eugenia Levi, PharmD,³ Mark Lebwohl, MD⁵

¹Yale University, New Haven, CT, USA; ²Central Connecticut Dermatology Research, Cromwell, CT, USA; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ⁴CorEvitas, LLC, Waltham, MA, USA; ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA

Corresponding author:

Bruce Strober, MD, PhD

1 Willowbrook Road, Suite 2

Cromwell, CT 06416

Phone: 860-322-2222

Email: brucestrober30@me.com

Table S1. Demographics, clinical characteristics, and treatment history of all biologic-experienced and biologic-naïve patients who initiated secukinumab and maintained treatment at a 6- and/or 12-month follow-up visit

Characteristic	Maintained secukinumab at 6-month follow-up			Maintained secukinumab at 12-month follow-up		
	All patients (N=652)	Biologic experienced (n=460)	Biologic naïve (n=192)	All patients (N=390)	Biologic experienced (n=288)	Biologic naïve (n=102)
Age, mean (SD), years	51.3 (14.0)	52.1 (14.0)	49.4 (14.1)	51.8 (14.4)	52.5 (14.4)	49.5 (14.4)
Male, n (%) [n]	344 (52.8) [651]	243 (52.8) [460]	101 (52.9) [191]	224 (57.4) [390]	165 (57.3) [288]	59 (57.8) [102]
Race, n (%)	n=652	n=460	n=192	n=390	n=288	n=102
White	515 (79.0)	355 (77.2)	160 (83.3)	303 (77.7)	218 (75.7)	85 (83.3)
Black	20 (3.1)	16 (3.5)	— ^a	11 (2.8)	9 (3.1)	— ^a
Asian	71 (10.9)	60 (13.0)	— ^a	48 (12.3)	41 (14.2)	— ^a
Other/unknown ^b	46 (7.1)	29 (6.3)	17 (8.9)	28 (7.2)	20 (6.9)	8 (7.8)
Body weight, mean (SD), kg [n]	91.5 (24.1) [649]	92.0 (24.2) [457]	90.2 (23.9) [192]	89.7 (22.9) [390]	89.3 (23.2) [288]	90.7 (21.9) [102]
BMI category, n (%)	n=648	n=456	n=192	n=390	n=288	n=102
Normal/underweight (<25)	120 (18.5)	78 (17.1)	42 (21.9)	80 (20.5)	61 (21.2)	19 (18.6)

Overweight (25 to <30)	203 (31.3)	144 (31.6)	59 (30.7)	126 (32.3)	92 (31.9)	34 (33.3)
Obese (≥30)	325 (50.2)	234 (51.3)	91 (47.4)	184 (47.2)	135 (46.9)	49 (48.0)
Smoking history, n (%)	n=648	n=458	n=190	n=385	n=283	n=102
Never smoked	337 (52.0)	234 (51.1)	103 (54.2)	220 (57.1)	167 (59.0)	53 (52.0)
Former smoker	196 (30.2)	141 (30.8)	55 (28.9)	104 (27.0)	73 (25.8)	31 (30.4)
Current smoker	115 (17.7)	83 (18.1)	32 (16.8)	61 (15.8)	43 (15.2)	18 (17.6)
Psoriasis disease duration, mean (SD), years	15.9 (13.9)	17.7 (13.8)	11.6 (13.2)	16.4 (14.0)	17.9 (13.9)	12.4 (13.6)
Age at psoriasis diagnosis, mean (SD), years [n]	34.4 (16.4) [469]	32.5 (16.1) [284]	37.4 (16.4) [185]	34.3 (16.3) [285]	32.8 (16.3) [189]	37.4 (15.9) [96]
Psoriatic arthritis, n (%) [n]	340 (52.8) [644]	273 (60.1) [454]	67 (35.3) [190]	201 (52.9) [380]	168 (59.8) [281]	33 (33.3) [99]
Psoriatic arthritis disease duration, mean (SD), years	7.8 (9.4)	8.8 (9.9)	3.8 (5.1)	8.6 (9.9)	9.4 (10.2)	4.7 (6.9)
Baseline comorbidities, n (%)	n=652	n=460	n=192	n=389	n=287	n=102
Hypertension	262 (40.2)	198 (43.0)	64 (33.3)	167 (42.9)	131 (45.6)	36 (35.3)
Anxiety	151 (23.2)	110 (23.9)	41 (21.4)	74 (19.0)	56 (19.5)	18 (17.6)

Depression	136 (20.9)	106 (23.0)	30 (16.7)	70 (18.0)	55 (19.2)	15 (14.7)
Diabetes	102 (15.6)	86 (18.7)	16 (8.3)	59 (15.2)	47 (16.4)	12 (11.8)
Cardiovascular disease ^c	78 (12.0)	65 (14.1)	13 (6.8)	48 (12.3)	37 (12.9)	11 (10.8)
Other gastrointestinal disorder	73 (11.2)	65 (14.1)	8 (4.2)	45 (11.6)	40 (13.9)	5 (4.9)
Cancer ^d	36 (5.5)	25 (5.4)	11 (5.7)	18 (4.6)	16 (5.6)	2 (2.0)
No. of prior biologics, n (%)		n=460			n=288	
1	—	214 (46.5)	—	—	139 (48.3)	—
2	—	130 (28.3)	—	—	87 (30.2)	—
≥ 3	—	116 (25.2)	—	—	62 (21.5)	—

BMI, body mass index.

^a To maintain confidentiality, values based on ≤ 5 observations (cells containing “—”) are suppressed.

^b Includes Native American, Native Hawaiian, other Pacific Islander, and other.

^c Cardiovascular disease included baseline history of any of the following: cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, coronary artery disease, and congestive heart failure.

^d Cancer included lymphoma; lung, breast, or skin cancers (basal cell, squamous cell, or melanoma); and any other cancers.

Table S2. Demographics, clinical characteristics, and treatment history of biologic-experienced and biologic-naive patients who initiated and maintained secukinumab treatment at 6- and 12-month follow-up visits

Characteristic	Maintained secukinumab at 6- and 12-month follow-ups		
	All patients (N=326)	Biologic experienced (n=244)	Biologic naive (n=82)
Age, mean (SD), years	51.8 (14.0)	52.2 (14.0)	50.4 (13.8)
Men, n (%)	192 (58.9)	142 (58.2)	50 (61.0)
Race, n (%)	n=326	n=244	n=82
White	249 (76.4)	180 (73.8)	69 (84.1)
Black	9 (2.8)	8 (3.3)	— ^b
Asian	45 (13.8)	40 (16.4)	— ^b
Other/unknown ^a	23 (7.1)	16 (6.6)	7 (8.5)
Body weight, mean (SD), kg	90.1 (23.1)	89.4 (23.7)	92.0 (21.3)
BMI category, n (%)	n=326	n=244	n=82
Normal/underweight (< 25)	64 (19.6)	51 (20.9)	13 (15.9)
Overweight (25 to < 30)	106 (32.5)	78 (32.0)	28 (34.1)
Obese (≥ 30)	156 (47.9)	115 (47.1)	41 (50.0)
Smoking history, n (%)	n=325	n=243	n=82
Never smoked	185 (56.9)	141 (58.0)	44 (53.7)
Former smoker	86 (26.5)	61 (25.1)	25 (30.5)
Current smoker	54 (16.6)	41 (16.9)	13 (15.9)
Psoriasis disease duration, mean (SD), years	15.6 (13.1)	16.9 (13.1)	11.9 (12.8)

Age at psoriasis diagnosis, mean (SD), years	34.9 (16.3)	33.1 (16.0)	38.7 (16.2)
Psoriatic arthritis, n (%)	166 (52.2)	138 (58.0)	28 (35.0)
Psoriatic arthritis disease duration, mean (SD), years	8.2 (9.8)	9.0 (10.2)	4.5 (6.3)
Baseline comorbidities, n (%)	n=326	n=244	n=82
Hypertension	146 (44.8)	114 (46.7)	32 (39.0)
Anxiety	65 (19.9)	49 (20.1)	16 (19.5)
Depression	63 (19.3)	50 (20.5)	13 (15.9)
Diabetes mellitus	51 (15.6)	41 (16.8)	10 (12.5)
Cardiovascular disease ^c	38 (11.7)	31 (12.7)	7 (8.5)
Other gastrointestinal disorder	39 (12.0)	35 (14.3)	4 (4.9)
Cancer/malignancy ^d	14 (4.3)	12 (4.9)	2 (2.4)
No. of prior biologics, n (%)	n=326	n=244	n=82
1	120 (36.8)	120 (49.2)	—
2	72 (22.1)	72 (29.5)	—
≥3	52 (16.0)	52 (21.3)	—

BMI, body mass index.


^a Includes Native American, Native Hawaiian, other Pacific Islander, and other.


^b To maintain confidentiality, values based on ≤ 5 observations (cells containing “—”) are suppressed.

^c Cardiovascular disease included baseline history of any of the following: cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, coronary artery disease, and congestive heart failure.

^d Cancer included lymphoma; lung, breast, or skin cancers (basal cell, squamous cell, or melanoma); and any other cancers.

Figure S1. Improvements in mean (SD) **(A)** BSA, **(B)** IGA, and **(C)** PASI from baseline to 6- and 12-month follow-up among patients with psoriasis who initiated and maintained secukinumab at both follow-up visits^a




C**Overall PASI**

BSA, body surface area; IGA, 5-Point Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.

^a Labels across baseline and follow-up visits represent mean (SD) differences.

Figure S2. Improvements in categorical IGA categories from baseline to 6- and 12-month follow-up visits in **(A)** biologic-experienced and **(B)** biologic-naïve patients with psoriasis who initiated and maintained secukinumab at both visits



IGA, 5-point Investigator's Global Assessment.